Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Pacific Edge Limited (PEB.NZ)
Dunedin, NZ
Based in Dunedin, New Zealand, Pacific Edge Limited, established in 2001, operates as a cancer diagnostics firm. The company's core mission involves the research, development, and commercialization of advanced diagnostic and prognostic tools aimed at the early identification and ongoing management of various cancers. Its diagnostic solutions are accessible in New Zealand, the United States, Australia, and Singapore, with operations structured across Commercial and Research segments. A key offering is the Cxbladder suite, a collection of genomic urine tests specifically designed for detecting and managing bladder cancer. Within this suite, Cxbladder Resolve aids in identifying patients likely to present with more aggressive or advanced bladder cancer. Cxbladder Triage helps pinpoint individuals with haematuria who exhibit a low probability of bladder cancer, while Cxbladder Detect offers a non-invasive method for identifying bladder and other urinary tract cancers. Furthermore, Cxbladder Monitor facilitates continuous surveillance for disease recurrence in bladder cancer patients. Beyond its focus on bladder cancer, Pacific Edge is actively developing additional diagnostic innovations. These include Cxcolorectal, a prognostic gene signature for assessing outcomes in patients diagnosed with stage II or stage III colorectal cancers, alongside pipeline products targeting gastric, endometrial cancers, and melanoma.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.85% | -1.85% | +51.43% | +32.50% | +73.20% | +43.24% | +227.16% | -43.01% | -78.10% | -54.16% | +19.28% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Diagnostics & Research: +7.9%-47.4% Q1'26: -50.7% (vs Q1'24)
-
EPS growth Medical - Diagnostics & Research: +30.8%-2.7% Q1'26: +6.3% (vs Q1'24)
-
FCF margin FCF growth · Medical - Diagnostics & Research: +32.2%-295.0% Q1'26: -233.4% (vs Q1'24)
-
EBIT margin Medical - Diagnostics & Research: +9.6%-329.1% Q1'26: -316.8% (vs Q1'24)
-
ROIC Medical - Diagnostics & Research: +5.2%-907.8% Q1'26: -1,634.5% (vs Q1'24)
-
Share dilution Medical - Diagnostics & Research: 0.0%+16.4% Q1'26: +24.9% (vs Q1'24)
-
Debt / EBITDA Net debt/EBITDA · Medical - Diagnostics & Research: -0.13×-0.04× Q1'26: -0.02× (vs Q1'24)
| Metric |
Mar 2015 actual |
Mar 2016 actual |
Mar 2017 actual |
Mar 2018 actual |
Mar 2019 actual |
Mar 2020 actual |
Mar 2021 actual |
Mar 2022 actual |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 1 Rev. Ana. 2 EPS Ana. |
Mar 2027 1 Rev. Ana. 2 EPS Ana. |
Mar 2028 1 Rev. Ana. 2 EPS Ana. |
Mar 2029 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
1.90M
est: 3.26M (-41.7%)
|
4.98M
est: 6.25M (-20.4%)
|
8.06M
est: 9.20M (-12.4%)
|
3.40M
est: 4.73M (-28.2%)
|
3.82M
est: 6.50M (-41.3%)
|
4.37M
est: 5.30M (-17.5%)
|
2.15M
est: 10.23M (-79.0%)
|
11.45M
est: 13.44M (-14.8%)
|
19.62M
est: 21.78M (-10.0%)
|
26.06M
est: 24.25M (+7.5%)
|
21.85M
est: 22.75M (-4.0%)
|
12.45M
12.45M – 12.45M
-45.3% YoY
|
18.67M
18.67M – 18.67M
+49.9% YoY
|
36.67M
36.67M – 36.67M
+96.4% YoY
|
59.65M
59.65M – 59.65M
+62.7% YoY
|
| EBITDA |
-12.50M
est: -3.26M (-283.4%)
|
-17.39M
est: -6.25M (-178.2%)
|
-22.28M
est: -9.20M (-142.1%)
|
-20.94M
est: -4.73M (-342.4%)
|
-19.03M
est: -6.50M (-192.7%)
|
-18.41M
est: -5.30M (-247.3%)
|
-15.44M
est: -10.23M (-51.0%)
|
-21.80M
est: -13.44M (-62.2%)
|
-32.80M
est: -21.78M (-50.6%)
|
-37.10M
est: -24.25M (-53.0%)
|
-31.76M
est: -22.75M (-39.6%)
|
-12.45M
-12.45M – -12.45M
+45.3% YoY
|
-18.67M
-18.67M – -18.67M
-49.9% YoY
|
-36.67M
-36.67M – -36.67M
-96.4% YoY
|
-59.65M
-59.65M – -59.65M
-62.7% YoY
|
| EBIT |
-12.96M
est: -3.26M (-297.5%)
|
-17.89M
est: -6.25M (-186.3%)
|
-22.82M
est: -9.20M (-148.0%)
|
-21.45M
est: -4.73M (-353.1%)
|
-19.34M
est: -6.50M (-197.5%)
|
-19.84M
est: -5.30M (-274.3%)
|
-16.92M
est: -10.23M (-65.4%)
|
-23.87M
est: -13.44M (-77.6%)
|
-35.74M
est: -21.78M (-64.1%)
|
-39.50M
est: -24.25M (-62.9%)
|
-34.10M
est: -22.75M (-49.9%)
|
-12.45M
-12.45M – -12.45M
+45.3% YoY
|
-18.67M
-18.67M – -18.67M
-49.9% YoY
|
-36.67M
-36.67M – -36.67M
-96.4% YoY
|
-59.65M
-59.65M – -59.65M
-62.7% YoY
|
| Net Income |
-10.73M
est: -21.37M (+49.8%)
|
-15.68M
est: -24.98M (+37.2%)
|
-20.98M
est: -36.33M (+42.3%)
|
-19.64M
est: -33.70M (+41.7%)
|
-17.92M
est: -24.33M (+26.3%)
|
-18.89M
est: -26.79M (+29.5%)
|
-14.22M
est: -15.71M (+9.4%)
|
-19.79M
est: -15.83M (-25.0%)
|
-26.97M
est: -25.43M (-6.0%)
|
-29.54M
est: -30.03M (+1.7%)
|
-29.94M
est: -31.64M (+5.4%)
|
-44.40M
-50.08M – -38.72M
-40.3% YoY
|
-31.48M
-33.24M – -29.73M
+29.1% YoY
|
-15.26M
-67.03M – 26.10M
+51.5% YoY
|
-2.83M
-2.83M – -2.83M
+81.4% YoY
|
| SGA |
7.92M
est: 7.85M (+0.8%)
|
11.54M
est: 15.05M (-23.3%)
|
17.62M
est: 22.15M (-20.5%)
|
15.22M
est: 11.40M (+33.6%)
|
16.26M
est: 15.65M (+3.9%)
|
14.38M
est: 12.76M (+12.7%)
|
13.99M
est: 24.63M (-43.2%)
|
18.32M
est: 32.36M (-43.4%)
|
31.11M
est: 52.46M (-40.7%)
|
33.44M
est: 58.39M (-42.7%)
|
23.33M
est: 34.48M (-32.4%)
|
18.87M
18.87M – 18.87M
-45.3% YoY
|
28.29M
28.29M – 28.29M
+49.9% YoY
|
55.58M
55.58M – 55.58M
+96.4% YoY
|
90.42M
90.42M – 90.42M
+62.7% YoY
|
| EPS |
-0.03
est: -0.03 (-18.1%)
|
-0.04
est: -0.03 (-31.6%)
|
-0.05
est: -0.04 (-17.7%)
|
-0.04
est: -0.04 (-2.1%)
|
-0.03
est: -0.03 (-16.5%)
|
-0.03
est: -0.03 (+1.5%)
|
-0.02
est: -0.02 (-2.8%)
|
-0.03
est: -0.02 (-32.3%)
|
-0.03
est: -0.03 (-6.3%)
|
-0.04
est: -0.04 (+1.6%)
|
-0.04
est: -0.03 (-10.1%)
|
-0.05
-0.05 – -0.04
-40.3% YoY
|
-0.03
-0.04 – -0.03
+29.1% YoY
|
-0.02
-0.07 – 0.03
+35.0% YoY
|
0.00
0.00 – 0.00
+86.2% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-26 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-25 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-22 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-21 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-20 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-19 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-18 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-15 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-14 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-13 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-08 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-07 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-06 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-05 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-04 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-01 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-30 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-29 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-28 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-24 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-23 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-22 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-21 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-20 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-17 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-16 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Dimensional - International Core Equity 2 ETF DFIC | 0.00% | 11.9K | 0.22% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Parry Guilford | Chief Scientific Officer & Member of Scientific Advisory Board | 134.0K | — |
| Darrell Morgan | Chief Operating Officer | — | male |
| Glen Costin | President of Asia Pacific | — | — |
| Grant Gibson | Chief Financial Officer | — | male |
| James J. Vaughn | Chief Commercial Officer | — | male |
| Justin Harvey | Chief Technology Officer | — | — |
| Peter Meintjes | Chief Executive Officer | — | — |
| Tamer Aboushwareb | Chief Medical Officer | — | — |
| Andrew McIntosh | Chief Digital Officer | — | male |
| Zoe O'Donnell | Global Head of People & Culture | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for PEB.NZ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
